Suspected PAD
Leg symptoms or risk factors for PAD
All Pathways
Vascular SurgeryManagement
Peripheral Arterial Disease Management (ACC/AHA 2024)
Peripheral Arterial Disease Management (ACC/AHA 2024): Suspected PAD → Clinical Assessment → Ankle-Brachial Index (ABI) → ABI Result → Normal ABI (1.00-...
Pathway Overview
18 steps
Algorithm Steps
18 total
01Start 02Action Clinical Assessment
History, examination, risk factors
- Symptoms: claudication, rest pain, non-healing wounds
- Risk factors: smoking, diabetes, HTN, dyslipidemia, age >65
- Examine pulses (femoral, popliteal, DP, PT)
- Skin changes, hair loss, muscle atrophy
- Screen high-risk: diabetes, smoking hx, CAD, renal disease
03Action Ankle-Brachial Index (ABI)
First-line diagnostic test
- Normal: 1.00-1.40
- Borderline: 0.91-0.99
- Mild-moderate PAD: 0.41-0.90
- Severe PAD: ≤0.40
- Non-compressible: >1.40 (calcified vessels)
04Decision ABI Result
Determines diagnosis and severity
05Action Normal ABI (1.00-1.40)
PAD unlikely but consider exercise ABI
- If symptoms persist: exercise ABI
- 20% drop post-exercise = PAD
- Consider other causes of leg pain
- Risk factor modification regardless
06Action Borderline ABI (0.91-0.99)
Exercise ABI recommended
- Treadmill exercise test
- Positive if ABI drops >20% post-exercise
- Initiate medical therapy if confirmed
- Consider TBI if high suspicion
07Action Guideline-Directed Medical Therapy
Foundation for all PAD patients (Class I)
- High-intensity statin (LDL reduction >50%)
- Antiplatelet: aspirin 75-325 mg OR clopidogrel 75 mg
- Blood pressure control (<130/80 mmHg)
- Diabetes management (if applicable)
- Smoking cessation (CRITICAL)
08Decision Symptom Classification
Guides additional therapy
- Asymptomatic: no leg symptoms
- Claudication: leg pain with walking, relieved by rest
- CLTI: rest pain, tissue loss, gangrene (separate algorithm)
09Action Asymptomatic PAD
Medical therapy + surveillance
- GDMT as above
- Walking exercise encouraged
- Annual ABI monitoring
- Screen for other ASCVD (coronary, carotid)
- No routine revascularization
10Action Long-Term Surveillance
Ongoing monitoring and risk reduction
- Annual clinical assessment
- ABI if symptoms change
- Continue GDMT indefinitely
- Screen for progression to CLTI
- Manage concomitant CAD, cerebrovascular disease
11Outcome Stable PAD
Symptoms controlled with medical therapy; annual follow-up
12Outcome Disease Progression
5-10% progress to CLTI over 5 years; cardiovascular events more common
13Action Claudication Management
Exercise therapy first-line
- Supervised exercise therapy (Class I)
- 30-45 min sessions, 3x/week, 12 weeks minimum
- Cilostazol 100 mg BID if no CHF (Class IIa)
- Community/home-based exercise alternative
- Reassess after 3-6 months
14Action Cilostazol
Pharmacotherapy for claudication
- 100 mg PO BID
- Contraindicated in heart failure
- Trial 3-6 months for effect
- Modest improvement in walking distance
- Discontinue if no benefit
- Path rejoins step 10Shared downstream outcome
15Decision Revascularization Consideration
If lifestyle-limiting despite therapy
- Failed exercise program
- Lifestyle-limiting claudication despite GDMT
- Favorable anatomy
- Patient preference (shared decision-making)
- Not for mild or non-limiting claudication
16Action Revascularization Strategy
Endovascular vs surgical based on anatomy
- Endovascular: less morbidity, shorter recovery
- Surgical: more durable for complex disease
- TASC A/B: endovascular preferred
- TASC C/D: surgical often better
- CLTI algorithm for threatened limb
- Path rejoins step 10Shared downstream outcome
- Path rejoins step 10Shared downstream outcome
17Action Low ABI (≤0.90)
PAD confirmed
- Diagnoses PAD
- Correlate with symptoms
- Assess severity: 0.41-0.90 mild-moderate, ≤0.40 severe
- Initiate comprehensive PAD therapy
- Path rejoins step 07Shared downstream outcome
18Action Non-Compressible (>1.40)
Calcified vessels - use alternative tests
- Common in diabetes, CKD, elderly
- Use toe-brachial index (TBI)
- TBI <0.7 suggests PAD
- Toe pressure <30 mmHg = severe ischemia
- Pulse volume recordings (PVR)
- Path rejoins step 07Shared downstream outcome
Guideline Source
ACC/AHA 2024 Guideline for Management of Lower Extremity Peripheral Artery Disease
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- ABI may be falsely elevated in diabetics/CKD (calcified vessels)
- Toe pressures/TBI more accurate in diabetics
- Symptom-based classification doesn't capture all patients
- Shared decision-making essential for revascularization
- Does not cover upper extremity PAD
Applicable Regions
USEUGlobal
EU: ESVS 2024 guidelines for asymptomatic PAD/claudication
US: ACC/AHA 2024 is current standard
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Peripheral Arterial Disease Management (ACC/AHA 2024)?
The Peripheral Arterial Disease Management (ACC/AHA 2024) is a management clinical algorithm for Vascular Surgery. It provides a structured decision tree to guide clinical decision-making, based on ACC/AHA 2024 Guideline for Management of Lower Extremity Peripheral Artery Disease.
What guideline is the Peripheral Arterial Disease Management (ACC/AHA 2024) based on?
This algorithm is based on ACC/AHA 2024 Guideline for Management of Lower Extremity Peripheral Artery Disease (DOI: 10.1161/CIR.0000000000001251).
What are the limitations of the Peripheral Arterial Disease Management (ACC/AHA 2024)?
Known limitations include: ABI may be falsely elevated in diabetics/CKD (calcified vessels); Toe pressures/TBI more accurate in diabetics; Symptom-based classification doesn't capture all patients; Shared decision-making essential for revascularization; Does not cover upper extremity PAD. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Peripheral Arterial Disease Management (ACC/AHA 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free